Allergy · 2026
Investigation of Clinical and Immunological Features of Alopecia Areata With Comorbid Atopic Dermatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yan Xin, Xie Xinyang, Gao Xuemei, Tayier Munire, Dong Yi, Yang Yifeng, Liao Zhongmin, Cheang Sin Tong, Jiang Wenjing, Lin Naiyu, Ai Lu, Zhang Xingqi, Ye Yanting
Аннотация
BACKGROUND: Alopecia areata (AA) frequently co-occurs with atopic dermatitis (AD; AA-AD); however, AA-AD's features remain unclear.
OBJECTIVE: To elucidate the clinical and immunological features of AA-AD.
METHODS: Retrospective analysis of data from 123 AA-AD patients, 119 non-atopic AA patients, and 126 AD patients (2011-2024). Peripheral blood mononuclear cells (PBMCs), plasma, and scalp tissues from patients and healthy controls (HC) were examined by flow cytometry, multiplex cytokine assays, and immunofluorescence.
RESULTS: Clinically, AA-AD patients were younger than non-atopic AA and AD-only patients, showed more severe alopecia and longer duration, but milder eczema, and exhibited higher dust-mite allergy, total IgE (tIgE), and Eos counts/percentages than non-atopic AA, while showing more intrinsic AD and lower tIgE and Eos counts/percentages than AD-only patients. AA severity and duration were positively correlated with those of AD. Compared with AA-AD patients with AA-first onset and AA with intrinsic AD (AA-IAD) patients, AA-AD patients with AD-first onset and AA with extrinsic AD (AA-EAD) patients were younger, had more severe eczema, higher tIgE levels, and dust-mite allergy. Compared with the non-atopic AA group and HC, the AA-AD group showed elevated plasma IL-4/6/10/13 levels and increased Th2 cells and ILC2s (group 2 innate lymphoid cells) proportions in PBMCs, along with their IL-13 production, all of which were positively correlated with AA course. AA-AD scalp also showed that Th2 cells and ILC2s were most abundant.
CONCLUSION: AA-AD defines a distinct clinical-immunologic endotype of AA. AA and AD exhibit an asymmetric but bilateral interaction driven by Th2/ILC2s-IL-13-centered pathways, representing key mechanisms and targets for precision therapy.
OBJECTIVE: To elucidate the clinical and immunological features of AA-AD.
METHODS: Retrospective analysis of data from 123 AA-AD patients, 119 non-atopic AA patients, and 126 AD patients (2011-2024). Peripheral blood mononuclear cells (PBMCs), plasma, and scalp tissues from patients and healthy controls (HC) were examined by flow cytometry, multiplex cytokine assays, and immunofluorescence.
RESULTS: Clinically, AA-AD patients were younger than non-atopic AA and AD-only patients, showed more severe alopecia and longer duration, but milder eczema, and exhibited higher dust-mite allergy, total IgE (tIgE), and Eos counts/percentages than non-atopic AA, while showing more intrinsic AD and lower tIgE and Eos counts/percentages than AD-only patients. AA severity and duration were positively correlated with those of AD. Compared with AA-AD patients with AA-first onset and AA with intrinsic AD (AA-IAD) patients, AA-AD patients with AD-first onset and AA with extrinsic AD (AA-EAD) patients were younger, had more severe eczema, higher tIgE levels, and dust-mite allergy. Compared with the non-atopic AA group and HC, the AA-AD group showed elevated plasma IL-4/6/10/13 levels and increased Th2 cells and ILC2s (group 2 innate lymphoid cells) proportions in PBMCs, along with their IL-13 production, all of which were positively correlated with AA course. AA-AD scalp also showed that Th2 cells and ILC2s were most abundant.
CONCLUSION: AA-AD defines a distinct clinical-immunologic endotype of AA. AA and AD exhibit an asymmetric but bilateral interaction driven by Th2/ILC2s-IL-13-centered pathways, representing key mechanisms and targets for precision therapy.